The effectiveness of mood stabilizers and antiepileptic medication for the management of behaviour problems in adults with intellectual disability: a systematic review.

Bhaumik et al. (2008) hunted for solid proof that mood pills calm behavior in adults with intellectual disability. They screened every paper on lithium, carbamazepine, sodium valproate, and topiramate up to 2008. Only a handful of tiny, short studies met their rules.

The team graded each trial for quality. Most were case reports or open-label tests with no control group. The authors summed up what passed and flagged the flaws.

The review found weak but hopeful signs for lithium and some antiepileptic mood drugs. Problem behaviors dropped in a few adults, yet the studies were small and sloppy. Side-effect data were missing or poorly tracked.

The authors call the evidence “limited” and urge caution before prescribing.

Heavey et al. (2000) warned that 1990s ID psychopharmacology rested on shaky science. Bhaumik et al. (2008) echo that same worry eight years later, showing little progress in rigor.

Tarrant et al. (2018) ran a similar systematic review on methylphenidate for kids with ID. Both reviews find low-quality evidence and modest benefit, strengthening the pattern that medication studies in ID need better designs.

Eussen et al. (2016) cast a wider net, looking at all mental-health interventions for adults with mild ID. They too found thin evidence, but flagged group CBT as the lone approach with any support. Together these papers show that whether you pick pills or therapy, the data pool for adults with ID remains shallow.

If you support adults with ID who show aggression or self-injury, this review tells you to treat mood stabilizers as a trial, not a fix. Demand baseline data, side-effect logs, and a clear exit plan. Pair any med change with behavior data you collect yourself—direct observation beats vague nurse notes. Until stronger RCTs arrive, your clinical judgment and close monitoring remain the real safeguards.